What Ovagen Is
Ovagen is a synthetic tripeptide, Glu-Asp-Leu, classified within the peptide bioregulator family as hepatic-associated.
Ovagen occupies an unusual position. The tripeptide Glu-Asp-Leu is a real, catalogued chemical entity — it resolves to PubChem CID 444128, C15H25N3O8, 375.37 g/mol, matching our catalog record. What does not exist is any published study of it under the name Ovagen.
Research use only. Supplied for laboratory research. Not for human or veterinary use. No marketing authorisation exists in any jurisdiction and no therapeutic claim is made.
Known Sequence, Unstudied Trade Name
This distinction matters more than it first appears. A compound can be structurally well defined and biologically uncharacterised at the same time, and Glu-Asp-Leu is that case: the molecule is unambiguous, while its proposed hepatic role rests entirely on the family's classification scheme rather than on an experiment.
A PubMed search returns no study whose title names Ovagen. No published work establishes an effect on liver function, lipid metabolism, or any other endpoint attributed to it, and no amount is established for any species.
The Class-Level Literature, and Its Limits
The papers usually cited around this compound concern the family: the systematic review of peptide regulation of gene expression (Khavinson et al., Molecules 2021, PMID 34834147) and peptide regulation of cell differentiation (Khavinson et al., Stem Cell Rev Rep 2020, PMID 31808038).
Both are about short peptides as a class. Neither tested Glu-Asp-Leu. Presenting them as support for hepatic claims about Ovagen would attribute to one sequence what was argued about many.
Worth noting for anyone comparing within the family: Livagen (Lys-Glu-Asp-Ala) carries the same hepatic association and does have papers naming it directly. If hepatic association is the reason for the interest, Livagen is the better-documented starting point.
Structure and Handling
- Sequence. Glu-Asp-Leu, tripeptide.
- Formula. C15H25N3O8, 375.37 g/mol (PubChem CID 444128).
- Form. Lyophilised powder, ≥98% purity, third-party certificate of analysis per batch.
- Storage. Sealed vial at −20 °C, protected from light; reconstituted solution at 2–8 °C.
- Reconstitution. Bacteriostatic water down the vial wall, never onto the powder cake. Do not shake. See the reconstitution calculator.
Where to Look Instead
For compounds in this family with studies naming them: Vilon (Lys-Glu), Pancragen (Lys-Glu-Asp-Trp), Epithalon (Ala-Glu-Asp-Gly), Thymalin and Livagen. The full catalog with the evidence position for each is on our bioregulator overview.
Sequence-Level Context: What Tripeptide Chemistry Predicts — and Does Not Confirm
Glu-Asp-Leu is a linear tripeptide carrying two acidic residues flanking a hydrophobic leucine at the C-terminus. This charge distribution is not arbitrary in the bioregulator classification scheme: Khavinson's group has argued, across multiple class-level papers, that short peptides exert tissue-specific effects by acting as complementary ligands to promoter regions of target genes, with specificity proposed to arise partly from residue charge and geometry rather than from receptor binding in the classical pharmacological sense.[3] That mechanistic proposal is itself contested — the evidence base is predominantly computational and cell-culture-level, and the gene-regulatory model has not been subjected to a prospective RCT in any organ system.[4]
For Glu-Asp-Leu specifically, no binding assay, transcriptomic experiment, or reporter-gene study has been published under this sequence or under the Ovagen trade name. Mechanistic inference from class-level theory is therefore the only available framework — and it is framework without measurement. The physicochemical properties are unambiguous: the peptide is freely water-soluble, carries a net negative charge at physiological pH (predicted pI approximately 3.5 based on residue pKa values for glutamic acid and aspartic acid), and has a molecular weight of 375.37 g/mol (PubChem CID 444128, formula C₁₅H₂₅N₃O₈). These properties are calculated from structure and do not depend on biological experiments. What they do not reveal is whether the sequence interacts with any hepatic gene promoter, hepatocyte receptor, or metabolic pathway at any concentration in any model. Stating otherwise would be an inference misrepresented as a finding.
Researchers evaluating this sequence for any planned experiment should note that the tripeptide's short length renders it a substrate for rapid proteolysis in biological fluids; unmodified Glu-Asp-Leu has no reported protease resistance, and no plasma half-life data exist in the published record. Route considerations and stability profiling would therefore need to precede any functional assay design.[3]
Documented Comparators: Tripeptides With Hepatic-Associated Literature
Because no published data exist for Ovagen itself, a responsible evidence map requires identifying what is documented among structurally or functionally adjacent short peptides in the hepatic-bioregulator category. This comparison is not evidence for Glu-Asp-Leu; it delineates the gap.
| Compound | Sequence | PubChem CID | Hepatic Association | Peer-Reviewed Studies Naming Compound | Best Available Model |
|---|---|---|---|---|---|
| Ovagen | Glu-Asp-Leu | 444128 | Yes (classification only) | 0 | None |
| Livagen | Lys-Glu-Asp-Ala | Not assigned in CID as of audit date | Yes (same family classification) | Limited; named in class-level reviews; no independent RCT | Cell-culture / computational |
| Epitalon | Ala-Glu-Asp-Gly | 219042 | Pineal/aging focus; hepatic not primary claim | Multiple (Khavinson group); primarily rodent and cell-based | Rodent in vivo[5] |
| BPC-157 | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15-mer) | 9941957 | Hepatoprotective effects reported | Multiple rodent studies; no human RCT | Rodent in vivo[6] |
The table makes explicit what prose risks obscuring: Ovagen sits at the furthest end of the evidence spectrum even within a family that is itself predominantly preclinical. BPC-157, while structurally unrelated (a 15-mer with a distinct sequence), is included because it represents the current ceiling of hepatic peptide research — rodent models with observable endpoints — and even that body of work has not produced human trial data.[6] The gap between BPC-157's evidence base and Ovagen's is the gap between "limited rodent data" and "no published data." Researchers whose hypothesis requires a hepatic short peptide with at least some empirical foundation should treat Livagen or BPC-157 as better-characterised starting points, with the caveat that neither has human efficacy data and the class-level mechanism itself remains unvalidated in prospective study.[3][4]
Regulatory Status and Research Classification
Ovagen holds no marketing authorisation in any jurisdiction examined: it does not appear in the European Medicines Agency's public product registry, the FDA's Drugs@FDA database, or the WHO INN list. It has not been assigned an International Nonproprietary Name. Its status in jurisdictions that regulate peptide bioregulators as pharmaceutical preparations — Russia and several post-Soviet states, where Khavinson-group compounds have been evaluated under GOST and Russian Pharmacopoeia standards — cannot be confirmed from English-language regulatory databases, and no peer-reviewed source in the PubMed record characterises its regulatory position there.[4]
For research classification purposes, Glu-Asp-Leu is commercially available as a synthetic research chemical. It is not a scheduled substance under the UN drug conventions, and it does not appear on WADA's current Prohibited List (2024 version); however, researchers operating in performance-sport-adjacent contexts should consult WADA's peptide hormone section independently, as classification criteria can change and short peptides with proposed endocrine-adjacent activity have attracted regulatory scrutiny as a category.[7] No doping control method specific to Glu-Asp-Leu is described in the analytical literature.
Because no preclinical safety package — including genotoxicity, acute toxicity, or repeat-dose studies — has been published for this sequence, the compound lacks the foundational documentation that would normally precede any structured research programme. Institutional biosafety and ethics review processes will require researchers to characterise this absence explicitly when submitting protocols. The appropriate framing in any such submission is that Glu-Asp-Leu is a structurally defined, commercially sourced tripeptide with no published toxicology, no published efficacy data, and no regulatory history in the indication of interest.
